This educational activity is planned in accordance with the AASLD Financial Disclosure Policy and the ACCME Standards for Integrity and Independence for Accredited Continuing Education by members of the CME Committee and the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distribuing healthcare goods and services used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies and their view of the relevance of the relationship to the education.The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contra-indications and warnings.The following financial disclosures are below:Jose Debes: Nothing to DiscloseAmir Hossein Guogol: Nothing to DiscloseYuko Kono:Research Grants: Bracco Diagnostics, Canon Medical Systems Corporation